Polatuzumab vedotin

Generic Name
Polatuzumab vedotin
Brand Names
Polivy
Drug Type
Biotech
Chemical Formula
-
CAS Number
1313206-42-6
Unique Ingredient Identifier
KG6VO684Z6
Background

Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrul...

Indication

Polatuzumab vedotin is used in combination with bendamustine and rituximab to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies. In Canada, this indication is approved for patients who are not eligible for autologous stem cell transplant and have received at least one p...

Associated Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma, High-grade B Cell Lymphoma (HGBCL), Large B Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Relapsed Diffuse large B-cell lymphoma NOS
Associated Therapies
-
Clinical Trials
Related News

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Posted Date
2020-12-14
Last Posted Date
2024-08-26
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
41
Registration Number
NCT04665765
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

City of Hope Medical Center, Duarte, California, United States

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

First Posted Date
2020-12-09
Last Posted Date
2024-01-08
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
63
Registration Number
NCT04659044
Locations
🇺🇸

Siouxland Regional Cancer Center, Sioux City, Iowa, United States

🇺🇸

Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States

🇺🇸

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

and more 2 locations

A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

First Posted Date
2020-11-12
Last Posted Date
2020-11-12
Lead Sponsor
Jiangsu Cancer Institute & Hospital
Target Recruit Count
35
Registration Number
NCT04624893
Locations
🇨🇳

Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2020-10-29
Last Posted Date
2023-01-25
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
350
Registration Number
NCT04607772
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

🇺🇸

US Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States

🇺🇸

University of Texas Southwestern, Dallas, Texas, United States

and more 15 locations

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL

First Posted Date
2020-10-20
Last Posted Date
2024-11-05
Lead Sponsor
University of Rochester
Target Recruit Count
39
Registration Number
NCT04594798
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

POLA+BR for Relapsed or Refractory DLBCL

Phase 2
Withdrawn
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Drug: Polatuzumab Vedotin
First Posted Date
2020-09-01
Last Posted Date
2022-05-09
Lead Sponsor
University of Colorado, Denver
Registration Number
NCT04535102

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

First Posted Date
2020-07-29
Last Posted Date
2023-10-26
Lead Sponsor
New York Medical College
Target Recruit Count
20
Registration Number
NCT04491370
Locations
🇺🇸

New York Medical Center, Valhalla, New York, United States

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

First Posted Date
2020-07-21
Last Posted Date
2024-03-20
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
49
Registration Number
NCT04479267
Locations
🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

First Posted Date
2020-03-27
Last Posted Date
2023-10-30
Lead Sponsor
Mayo Clinic
Target Recruit Count
50
Registration Number
NCT04323956
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

First Posted Date
2020-01-22
Last Posted Date
2023-03-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
42
Registration Number
NCT04236141
Locations
🇨🇳

Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China

🇨🇳

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China

🇨🇳

West China Hospital, Sichuan University, Chengdu, China

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy